Highest-materiality recent filing
Microbot Medical CEO to present at SRS annual meeting; highlights LIBERTY System and recent award
CEO Harel Gadot to present at Society of Robotic Surgery annual meeting July 23-26 in Fort Lauderdale.
Microbot Medical reports >100% revenue and customer growth for Q2 2026 vs Q1 2026
Revenue and new customers grew more than 100% in Q2 2026 compared to Q1 2026.
Microbot Medical signs manufacturing agreement with Sanmina for LIBERTY System
Entered into Letter of Agreement with Sanmina Corporation to manufacture the LIBERTY Endovascular Robotic System.
Microbot Medical wins Surgical Robotics Industry Innovative Start-Up Award for LIBERTY System
Won the Innovative Start-Up Award from Surgical Robotics Technology (SRT) for the LIBERTY Endovascular Robotic System.
Microbot Medical's LIBERTY System adopted by first Pennsylvania academic center; now in 7 states
Globally recognized academic center in Pennsylvania is first in state to adopt LIBERTY Endovascular Robotic System.
Agreement with Lovell Government Services (SDVOSB) to market LIBERTY Endovascular Robotic System to federal healthcare systems.
Microbot Medical secures first Midwest account, Michigan health system adopts LIBERTY System
First Midwest-based account: a large Michigan healthcare system adopts LIBERTY Endovascular Robotic System.
Microbot Medical secures first North Carolina customer for LIBERTY robotic system
New customer is a leading academic center and multi-hospital network covering the entire state.
Microbot Medical receives Israeli regulatory approval for LIBERTY System, first outside U.S.
Israeli Ministry of Health's AMAR Division grants marketing clearance for LIBERTY Endovascular Robotic System in Israel.
Conference call on Monday, May 18 at 3 PM ET to address recent unaffiliated third-party article's misleading statements.
Microbot Medical records first revenue from LIBERTY; Q2 revenue already exceeds Q1
Recorded revenue from limited market release of LIBERTY System in Q1 2026; transitioned to full market release in Q2.
LIBERTY Endovascular Robotic System won accounts in key U.S. territories, including two ACCESS-PVI trial sites.
Microbot Medical appoints Alon Tamir VP Sales EMEA, targets CE mark by end of 2026
Alon Tamir named Vice President of Sales for Europe, Middle East and Asia (EMEA) to lead international expansion.
Microbot Medical highlights updated SIR/CIRSE guidelines strengthening LIBERTY system position
Updated joint guidelines from SIR and CIRSE cover radiation exposure and musculoskeletal risks for interventional radiology staff.
CEO Harel Gadot will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026 at 10:15 a.m. ET.
LIBERTY adopted by multiple healthcare systems including Emory Healthcare and Tampa General Hospital during limited market release.
Microbot Medical files prospectus supplement for existing ATM program with H.C. Wainwright
Company files prospectus supplement for ATM program with Wainwright; aggregate offering price up to $39,230,691.
Emory performs first robotic PAE and Y-90 mapping using Microbot's LIBERTY System
World's first robotic prostate artery embolization (PAE) for BPH performed with LIBERTY at Emory.
Microbot Medical's LIBERTY pivotal study published in JVIR; full market launch in April 2026
ACCESS-PVI study published in JVIR, a top radiology journal, after independent peer review.
Microbot Medical to present at Roth Conference; full LIBERTY market release on track for April 2026
CEO Harel Gadot to present fireside Q&A at Roth Annual Growth Conference on March 23, 2026 at 4:00 pm PT.
Microbot Medical to present at Oppenheimer Healthcare Conference on March 19, 2026
CEO Harel Gadot will present live at 8:40am ET on March 19, highlighting LIBERTY system milestones.
Microbot Medical praises new AMA radiation policy; cites 92% cut with LIBERTY robot
AMA adopted new policy in late 2025 to strengthen protections from ionizing radiation; Microbot commends the move.
No business disruption in USA or Israel; all personnel operational, lead manufacturing partner fully functional.
Tampa General Hospital first in Florida to adopt Microbot's LIBERTY robotic system
Tampa General Hospital (TGH) becomes first Florida health system to adopt LIBERTY Endovascular Robotic System after FDA 510(k) clearance.
Microbot Medical raises executive salaries, bonuses; CEO gets $140k special bonus
CTO Simon Sharon base salary increased to NIS 1,008,000; CFO Rachel Vaknin to NIS 756,000, retroactive Jan 1, 2026.
Microbot Medical CEO to speak at SAGES NBT Innovation Weekend panel on endovascular robotics
CEO Harel Gadot will be a featured panelist at The Surgical Disruptive Technology Summit (Feb 19-21, 2026 in Houston, TX).
LIBERTY Endovascular Robotic System highlighted at ISET conference Feb 9-12, 2026 in Miami Beach.
Microbot attending SIO conference; LIBERTY limited release ongoing, full release planned April 2026
Microbot Medical (MBOT) attending Society of Interventional Oncology conference Feb 4-8, 2026 in Savannah, GA.
Received FDA 510(k) clearance for LIBERTY, first single-use remotely operated robotic system for peripheral endovascular procedures.
Emory University Hospital in Atlanta is first hospital globally to adopt Microbot's LIBERTY Endovascular Robotic System for patient care.
Microbot Medical launches limited U.S. commercial release of LIBERTY robotic system
LIBERTY Endovascular Robotic System now commercially available in U.S. on a limited basis after FDA 510(k) clearance in September 2025.
Microbot Medical to debut LIBERTY System at CIO meeting; hires commercial team
First commercial exhibition of LIBERTY Endovascular Robotic System at CIO symposium in Miami, Oct 17-19, 2025.
Microbot partners with US logistics provider; LIBERTY launch on track for Q4 2025
Partnered with an experienced medtech 3PL company for inventory management and order fulfillment.
Microbot Medical completes final PIO exercise closing, raising $29.2M initial gross proceeds
Three closings: $25.2M (first), $1.2M (second), $2.8M (third) – total $29.2M gross proceeds before fees.
Microbot Medical issues stock and options in two unregistered transactions
Holder exercised 600,000 series H PIOs at $2.10/share, receiving 600,000 shares and new series J PIOs.
Japanese Patent Office granted first Japan patent covering core LIBERTY System technology for compact robotic surgical tool.
CEO Harel Gadot will be interviewed on Benzinga All Access at 10:45am ET on September 24, 2025.
CEO/Harel Gadot gets $158,115; CTO Simon Sharon ~$64,200; CEO Rachel Vaknin ~$32,500 for prior salary waivers in 2023 restructuring.
Microbot Medical raises $25.2M in first close of PIO exercise; potential total $92.2M
First closing on Sep 16 generated ~$25.2M gross; second closing expected by Oct 15 for ~$4M.
Microbot Medical releases updated investor presentation, presents at H.C. Wainwright conference
Updated presentation materials released on September 9, 2025, available on company website.
Microbot Medical receives FDA 510(k) clearance for LIBERTY Endovascular Robotic System
FDA 510(k) clearance for LIBERTY System, first single-use remotely operated robotic system for peripheral endovascular procedures.
Microbot Medical issues 4.06M shares on option exercises, raises ~$8.6M
Issued 300,000 Series H option shares at $2.10 and 3,755,870 Series I option shares at $2.13.
Microbot Medical issues ~3M shares upon option exercises, raising ~$5.9M gross
Issued 2,967,953 shares from Series E, G, H preferred investment options between Aug 11-25, 2025.
Microbot Medical granted USPTO patent expanding LIBERTY system TAM to 6M+ US procedures
Patent covers modular robotic system with interchangeable tool-receiver units attachable to base.
Microbot Medical raises ~$7.6M from option exercises, receives NIS 2.15M IIA grant
Issued 4,344,286 shares at $1.75 upon exercise of Series G options, gross proceeds $7.6M.
Microbot Medical issues 2.4M shares on warrant exercises, raising $4.2M
Issued 2,395,715 shares of common stock upon exercise of Series G preferred investment options since July 17, 2025.
Microbot Medical appoints Christina Bailey as VP of Sales ahead of LIBERTY launch
Christina Bailey named VP of Sales; reports to CEO Harel Gadot.
Microbot Medical raises ~$3.0M via exercise of Series F and G options
Issued 1,808,336 shares upon exercise of 1,025,000 Series G and 783,336 Series F options since June 18, 2025.
Participates in Society of Robotic Surgery annual meeting July 16-20 in Strasbourg, France.
Microbot Medical added to Russell Microcap Index effective June 30, 2025
Added to the Russell Microcap Index as of market open on June 30, 2025, with automatic inclusion in growth and value style indexes.
On November 21, 2023, Microbot Medical Inc. (the “Company”) announced the appointment of Dr. Juan Diaz-Cartelle, age 48, as the Company’s new Chief Medical Officer (“CMO”).
On August 29, 2023, Eyal Morag, the Company’s Chief Medical Officer, resigned from his position with the Company, effective November 29, 2023.
As of April 1, 2022, the Company appointed Rachel Vaknin, age 43, as its Chief Financial Officer.
As of April 1, 2022, David Ben Naim, the Chief Financial Officer of Microbot Medical Inc. (the “Company”), resigned from his position with the Company, effective immediately.
Max materiality 0.85 · Median 0.60 · Most common event other_material